 Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Descriptor ID |
D003924
|
| MeSH Number(s) |
C18.452.394.750.149 C19.246.300
|
| Concept/Terms |
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Noninsulin-Dependent
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- NIDDM
- Diabetes Mellitus, Noninsulin Dependent
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Noninsulin-Dependent Diabetes Mellitus
- Noninsulin Dependent Diabetes Mellitus
- Maturity-Onset Diabetes
- Diabetes, Maturity-Onset
- Maturity Onset Diabetes
- Type 2 Diabetes
- Diabetes, Type 2
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in this website by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 8 | 3 | 11 | | 1997 | 3 | 4 | 7 | | 1998 | 8 | 2 | 10 | | 1999 | 8 | 1 | 9 | | 2000 | 9 | 2 | 11 | | 2001 | 3 | 5 | 8 | | 2002 | 9 | 1 | 10 | | 2003 | 19 | 2 | 21 | | 2004 | 13 | 4 | 17 | | 2005 | 17 | 10 | 27 | | 2006 | 27 | 3 | 30 | | 2007 | 36 | 8 | 44 | | 2008 | 28 | 6 | 34 | | 2009 | 47 | 4 | 51 | | 2010 | 41 | 11 | 52 | | 2011 | 40 | 13 | 53 | | 2012 | 50 | 13 | 63 | | 2013 | 53 | 8 | 61 | | 2014 | 58 | 15 | 73 | | 2015 | 70 | 10 | 80 | | 2016 | 56 | 12 | 68 | | 2017 | 66 | 18 | 84 | | 2018 | 87 | 16 | 103 | | 2019 | 77 | 11 | 88 | | 2020 | 99 | 9 | 108 | | 2021 | 111 | 8 | 119 | | 2022 | 116 | 4 | 120 | | 2023 | 122 | 3 | 125 | | 2024 | 78 | 10 | 88 | | 2025 | 83 | 5 | 88 | | 2026 | 50 | 4 | 54 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
Gutierrez-Colina AM, Neiser A, Aichele S, Velasco P, B Goldschmidt A, Lavender JM, Dailey R, Sanchez N, Kelsey MM, Shomaker LB. Evaluating temporal associations between executive functioning, stress and physical activity among adolescents at risk for type 2 diabetes: protocol for an ecological momentary assessment study. BMJ Open. 2026 08 28; 16(8):e116178.
-
Salive ME, Tjaden AH, Ames JR, Crandall JP, Dabelea D, Hazuda HP, Heckman-Stoddard BM, Huckfeldt PJ, Kuo S, Strotmeyer ES, Temprosa M, Venditti EM. Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes. JAMA. 2026 08 18; 336(7):577-586.
-
Valdez Y, Segev N, Parimi N, Vegesna M, Brown EA, Samuels S, Van Name M, Shah AS, Wolf RM. Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis. J Pediatr Endocrinol Metab. 2026 Oct 26; 39(10):1007-1016.
-
Wang Y, Sargent JL, Mathieu C, Vazquez-Arreola E, Perreault L, Loos RJF, Lim LL, Sandforth L, Hanson RL, Kullmann S, Sbierski-Kind J, Brucker SY, Hrabé de Angelis M, Theiss F, Icks A, Mohebbi D, Stefan N, Mohan V, Wang T, Preissl H, Bergman M, Tuomilehto J, Hivert MF, Franks PW, Birkenfeld AL. Type 2 diabetes prevention across the life course. Nat Med. 2026 Aug; 32(8):2757-2773.
-
Pistenmaa CL, Doherty L, Hermann EA, Brown AL, Dabelea D, Holguin F, Watson K, Knowler WC, Temprosa M, Barr RG. Lung function after randomization to metformin, lifestyle intervention or placebo in the Diabetes Prevention Program Outcomes Study (DPPOS). Respir Med. 2026 Oct; 262:109077.
-
Wang N, DiCorpo DA, Zhang Y, Kleinbrink E, Arnett DK, Barnard J, Blangero J, Bowden DW, Carson AP, Chen YI, Chung MK, Curran JE, Darbar D, Duggirala R, Ellinor PT, Fatkin D, Fornage M, Heard-Costa N, He J, Hou L, Kardia SLR, Kooperberg C, Loos RJF, McManus DD, Mitchell BD, Minster RL, North KE, Psaty BM, Raffield LM, Redline S, Rich SS, Roden D, Rotter JI, Shoemaker MB, Smith JD, Van Wagoner DR, Aguet F, Ardlie K, Bis JC, Brody JA, Cade BE, Clish CB, de Vries PS, Floyd JS, Freedman BI, Gabriel S, Gerzsten RE, Goodarzi MO, Gu C, Guo X, Gupta N, Heckbert SR, Hsu S, Hung YJ, Kalyani RR, Kelly TN, Kinney GL, Li C, Liu S, Liu Y, Lloyd-Jones DM, Manson JE, Mathias RA, Mercader JM, Morrison AC, Naseri T, Onengut S, Palmer ND, Peyser PA, Qi Q, Raghavan S, Reiner AP, Rooney MR, Sevilla-Gonzalez M, Sarnowski C, Smith JD, Smith JA, Spartano NL, Tahir U, Taylor KD, Tobias DK, Tracy RP, Viali S, Wang H, Wood AC, Yanek LR, Zhao W, Zheng Y, Dupuis J, Liu CT, Sladek R, Wessel J, Meigs JB, Manning AK. Colocalization of eQTLs With Type 2 Diabetes and Glycemic Traits Using Whole-Genome Sequences in Diverse Populations From the NHLBI Trans-Omics in Precision Medicine (TOPMed) Program. Diabetes. 2026 Aug 01; 75(8):1477-1491.
-
DiStefano MJ, Zon J, Olson EG, Levy JF, Anderson GF, Alexander GC. Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey. J Manag Care Spec Pharm. 2026 Aug; 32(8):903-910.
-
Colangelo H, Nestler A, Lyon C. Not Just for Diabetes: The Next Frontier for GLP-1 Agonists. J Am Board Fam Med. 2026 Aug; 39(1).
-
van Baar MJB, Bjornstad P, Touw DJ, Joles JA, Krebber MM, Cherney DZI, van Raalte DH, Muskiet MHA. Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrol Dial Transplant. 2026 Jul 31; 41(8):1520-1528.
-
Xi Y, Thorand B, Schneider A, Wolf K, Dallavalle M, Nikolaou N, Linkohr B, Kronenberg F, Rathmann W, Schlesinger S, Herder C, Schwettmann L, Zeller T, Jumpertz von Schwartzenberg R, Breitner-Busch S, Peters A. Association of long-term exposure to air pollution, built environment and air temperature with the incidence of prediabetes phenotypes, and prediabetes remission and progression to type 2 diabetes: a longitudinal study in the KORA cohort. Diabetologia. 2026 Oct; 69(10):2819-2832.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|